reports
Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9,...
Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024 2024 OIS Retina and ARVO meetings are being held in Seattle, Washington BEDFORD, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, announced multiple presentations at the Ophthalmology...
Shutterstock Inc: 1 director
A director at Shutterstock Inc sold 5,439 shares at 42.910USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Fresh Del Monte Produce Inc. Reports First Quarter Earnings for Fiscal...
CORAL GABLES, Fla.--(BUSINESS WIRE)-- Fresh Del Monte Produce Inc. (NYSE: FDP), ("Fresh Del Monte" or the "Company") today reported financial results for the first quarter ended March 29, 2024. “We are pleased with the ongoing momentum in our higher-margin fresh and value-added segment. During the first quarter of 2024, this prioritized area of our business delivered 5% revenue growth driven by our strategic initiatives around distribution, pricing, and premiumization. While service level issues and competitive market pressures in North America and Europe reduced our banana revenue, we conti...
IFF Declares Dividend for Second Quarter 2024
NEW YORK--(BUSINESS WIRE)-- IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on July 10, 2024 to shareholders of record as of June 21, 2024. Welcome to IFF At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners ...
Ocular Therapeutix™ to Host Investor Day in New York City on Thursday,...
Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024 First quarter 2024 financial results to be reported on Tuesday, May 7, 2024 Investor Day to replace first quarter 2024 earnings conference call; quarterly calls to resume regular cadence with second quarter 2024 financial results BEDFORD, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for...
Fresh Del Monte and University of Granada Announce Expanded Partnershi...
MIAMI--(BUSINESS WIRE)-- , (NYSE: FDP) one of the world’s leading vertically integrated producers, marketers, and distributors of high-quality fresh and fresh-cut fruits and vegetables, and a prestigious Spanish university established in 1531 and a global hub for cutting-edge research, today announced an extended partnership that will look into how bioactive compounds from residues of different fruits can be used for medical and non-medical applications in the spirit of promoting health and well-being. The partnership comes after more than a year of initial research that looked into the effec...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
PEP PEPSICO INC.
TXN TEXAS INSTRUMENTS INCORPORATED
TRMK TRUSTMARK CORPORATION
SWN SOUTHWESTERN ENERGY COMPANY
SMTC SEMTECH CORPORATION
SATS ECHOSTAR CORPORATION CLASS A
RRC RANGE RESOURCES CORPORATION
NFG NATIONAL FUEL GAS COMPANY
MDWD MEDIWOUND
LWAY LIFEWAY FOODS INC.
HAS HASBRO INC.
FBP FIRST BANCORP
EQT EQT CORPORATION
DECK DECKERS OUTDOOR CORPORATION
CRK COMSTOCK RESOURCES INC.
VIRT VIRTU FINANCIAL INC. CLASS A
SYF SYNCHRONY FINANCIAL
HRTG HERITAGE INSURANCE HOLDINGS INC.
BSX. BELO SUN MINING CORP.
ORN ORION GROUP HOLDINGS
ITGR INTEGER HOLDINGS CORPORATION
PE. PURE ENERGY MINERALS LTD
DESP DESPEGAR.COM CORP.
AMRX AMNEAL PHARMACEUTICALS INC. CLASS A
NTB BANK OF N.T. BUTTERFIELD & SON
COOP MR. COOPER GROUP INC.
KTB KONTOOR BRANDS
ALXO ALX ONCOLOGY HOLDINGS
PRDO PERDOCEO EDUCATION CORP
LRN STRIDE INC
PRG PROG HOLDINGS INC
VRT VERTIV HOLDINGS CO (A)
AMAL AMALGAMATED FINANCIAL CORP
CGEM CULLINAN ONCOLOGY INC
RANI RANI THERAPEUTICS HLDGS INC
CR CRANE CO NEW
BGC BGC GROUP INC
SOWG SOW GOOD INC COM
Fresh Del Monte Produce Inc. to Report First Quarter 2024 Financial Re...
CORAL GABLES, Fla.--(BUSINESS WIRE)-- . (NYSE: FDP), (the “Company”) today announced that it will issue a press release on its first quarter financial results after market closing on Thursday, May 2, 2024 and will host its quarterly conference call that day at 4:45 p.m. Eastern Time to discuss the Company’s financial results. Hosting the call for the Company will be Mohammad Abu-Ghazaleh, Chairman and Chief Executive Officer, Monica Vicente, Senior Vice President and Chief Financial Officer, and Claudia Pou, Vice President, Corporate Communications. Institutional investors, analysts and othe...
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXL...
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy 46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the AXPAXLI arm, compared to 0% in the control arm No patients in the AXPAXLI group experienced worsening in DRSS compared to 12.5% in the control arm at 40 weeks AXPAXLI was generally well tolerated with no inflammation observed Ocular intends to present the Phase 1 HELIOS study at an upcoming meeting BEDFORD, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeut...
IFF to Release First Quarter 2024 Results on May 6, 2024
NEW YORK--(BUSINESS WIRE)-- IFF (NYSE:IFF) today announced that it will release its first quarter 2024 earnings results following the market close on Monday, May 6, 2024. The management team will host a live webcast on Tuesday, May 7, 2024 at 9:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the Company's website at . For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), an industry leader in food, beverage, h...
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key ...
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders Nadia K. Waheed, MD, MPH, Appointed Chief Medical Officer; Peter K. Kaiser, MD, to Become Chief Development Officer; Andrea Gibson, PhD, Named Vice President, Medical Collaborations; and Namrata Saroj, OD, to Become Development Strategy Consultant Dr. Waheed’s strong industry track record as a CMO and broad expertise in wet AMD and diabetic retinopathy support advancing the Phase 3 AXPAXLI™ program Dr. Kaiser’s vast leadership experience in numerous pivotal trials of approved wet AMD products enhances Oc...
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes Pre...
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO BEDFORD, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that Executive Chairman, Pravin U. Dugel, MD, is assuming t...
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule...
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics BEDFORD, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that it has granted inducement equity awards to its newly appoin...
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data...
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting Phase 2 data highlight consistent and sustained reductions in Intraocular Pressure (IOP), statistically significant (p
Moody's affirms International Flavors & Fragrances' Baa3 rating; outlo...
Moody's Ratings (Moody's) affirmed International Flavors & Fragrances, Inc.'s ("IFF") Baa3 issuer rating, Baa3 senior unsecured debt rating and its Prime-3 (P-3) rating for commercial paper. The outlook was changed to stable from negative. The stabilization of the outlook follows the company's rec...
IFF Completes Divestiture of Cosmetics Ingredients Business
NEW YORK--(BUSINESS WIRE)-- IFF (NYSE: IFF) today announced that it has completed the previously announced divestiture of its Cosmetic Ingredients business to Clariant, a sustainably focused specialty chemicals company. As a part of Clariant, the business will continue to deliver innovative ingredients for the cosmetic and personal care product portfolio. “At IFF, our strategic transformation is focused on bringing leading innovation to best serve target customers in our core businesses,” said IFF CEO Erik Fyrwald. “To do this, we are optimizing and streamlining our portfolio to drive simpli...
- Wedbush Research
KMX CARMAX INC.
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
SGMO SANGAMO THERAPEUTICS INC.
RHP RYMAN HOSPITALITY PROPERTIES INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PCRX PACIRA BIOSCIENCES INC.
NVCR NOVOCURE LTD.
NCMI NATIONAL CINEMEDIA INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MTH MERITAGE HOMES CORPORATION
LGIH LGI HOMES INC.
LEN LENNAR CORPORATION CLASS A
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
IMAX IMAX CORPORATION
GPRO GOPRO INC. CLASS A
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CNK CINEMARK HOLDINGS INC.
CMRX CHIMERIX INC
CCS CENTURY COMMUNITIES INC.
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
AMC AMC ENTERTAINMENT HOLDINGS INC. CLASS A
NFLX NETFLIX INC.
DHI D.R. HORTON INC.
FRX_CN FENNEC PHARMACEUTICALS
PVH PVH CORP.
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
ALBO ALBIREO PHARMA
ANAB ANAPTYSBIO INC.
KALA KALA PHARMACEUTICALS INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
ALPN ALPINE IMMUNE SCIENCES
ROKU ROKU INC. CLASS A
AMZN AMAZON.COM INC.
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SURF SURFACE ONCOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
BCEL ATRECA
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
AQST AQUESTIVE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
PRAX PRAXIS PRECISION MEDICINES
FUBO FUBOTV
CURA CURALEAF HOLDINGS
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
OMGA OMEGA THERAPEUTICS
LBPH LONGBOARD PHARMACEUTICALS
THRX THESEUS PHARMACEUTICALS
DSGN INC.
ATXS DESIGN THERAPEUTICS INC
AVTE ASTRIA THERAPEUTICS INC
RLYB AEROVATE THERAPEUTICS INC
KRTX RALLYBIO CORP
FUSN KARUNA THERAPEUTICS INC
VIGL FUSION PHARMACEUTICALS INC
EWTX VIGIL NEUROSCIENCE INC
EDGEWISE THERAPEUTICS INC
- Alicia Reese
- Michael Pachter
- Alicia Reese
- Matthew Weiss
- Michael Gerbino
- Michael Pachter
- Scott Devitt
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.